Novo Nordisk | NVO - Ebitda


Novo Nordisk reported DKK31.44B in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
ANI Pharmaceuticals USD 65.36M 5.76M Dec/2025
Aurora Cannabis CAD 18.48M 3.11M Dec/2025
Bausch Health Companies USD 837M 94M Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Canopy Growth CAD -2.87M 19.49M Dec/2025
Corcept Therapeutics USD 4.2M 6.5M Dec/2025
Drreddys Laboratories INR 21.59B 1.49B Dec/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
Merck USD 6.3B 2.09B Dec/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Novartis USD 5.3B 530M Mar/2026
Novo Nordisk DKK 34.72B 2.57B Mar/2026
Novo Nordisk DKK 31.44B 6.84B Sep/2025
Pacira USD 40.24M 1.53M Mar/2026
Perrigo USD 141.6M 1.34B Mar/2026
Phibro Animal Health USD 68.1M 6.2M Dec/2025
Prestige Brands USD 90.82M 3.99M Dec/2025
Sanofi EUR 3.31B 3.65B Mar/2026
Supernus Pharmaceuticals USD 29.23M 19.27M Mar/2026
Zoetis USD 939M 101M Dec/2025